The trial, led by Giselle Sholler, aims to assess the feasibility of using the OncInsights technology for personalized treatment planning in patients with refractory or recurrent neuroblastoma. Given the limited treatment options for this patient population, successful outcomes could position OncInsights as a valuable tool in precision oncology, potentially leading to partnerships with pharmaceutical companies focused on neuroblastoma therapies. The market for pediatric oncology is growing, and advancements in molecular-guided therapies may enhance competitive positioning against traditional treatment modalities. Diligence should focus on regulatory pathways, as the technology is not yet FDA-approved, and on the potential for scalability in clinical practice.